GLP-1 agonists have been shown to be beneficial in a lengthening list of diseases, but it seems Alzheimer's disease may not be among them. Novo Nordisk has just released the topline findings from two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results